These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39229338)

  • 1. Free energy landscape of the PI3Kα C-terminal activation.
    Kotzampasi DM; Papadourakis M; Burke JE; Cournia Z
    Comput Struct Biotechnol J; 2024 Dec; 23():3118-3131. PubMed ID: 39229338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.
    Jenkins ML; Ranga-Prasad H; Parson MAH; Harris NJ; Rathinaswamy MK; Burke JE
    Nat Commun; 2023 Jan; 14(1):181. PubMed ID: 36635288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
    Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
    PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
    Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
    Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
    Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
    J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
    Gkeka P; Papafotika A; Christoforidis S; Cournia Z
    J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
    Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
    Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryo-EM structures reveal two allosteric inhibition modes of PI3Kα
    Huang X; Wang K; Han J; Chen X; Wang Z; Wu T; Yu B; Zhao F; Wang X; Li H; Xie Z; Zhu X; Zhong W; Ren X
    Structure; 2024 Jul; 32(7):907-917.e7. PubMed ID: 38582077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
    Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
    Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight.
    Sharma J; Bhardwaj V; Purohit R
    ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.